A Look Into The Future Of NASH

The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.

Liver disease
A plethora of drug candidates are in development for NASH • Source: Shutterstock

Sometimes advances in drug development are like London buses: you wait for ages, and then loads turn up at once. This has certainly been the case in the non-alcoholic steatohepatitis (NASH) space, with several mid-stage trials yielding positive – or positive-ish – data in the past few months.

Key Takeaways
  • Madrigal’s resmetirom is likely to become the first drug approved in NASH later this year

But there is much more to come. Players including Novo Nordisk A/S, Boehringer Ingelheim GmbH, Pfizer Inc....

More from Business Strategy

More from In Vivo